



MISSISSIPPI DIVISION OF
MEDICAID

**MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting**

Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399

**August 14, 2018
10:00am to 5:00pm**

MINUTES

Committee Members Present:

Jeffrey A. Ali, M.D., M.Sc.
James B. Brock, M.D.
Logan Davis, Pharm.D., MBA
Naznin Dixit, M.D.
D. Stanley Hartness, M.D.
Karen Maltby, M.D.
Deborah Minor, Pharm.D.
Kim Rodgers, R.Ph..
Spencer Sullivan, M.D.
Mack Woo, M.D.

Committee Members Not Present:

Geri Lee Weiland, M.D.
Wilma Wilbanks, R.Ph.

Division of Medicaid Staff Present:

Jason Dees, D.O., Interim Medical Director
Terri Kirby, B.S.Pharm., R.Ph., Pharmacy Director
Gail McCorkle, R.Ph., Pharmacist III
Cindy Noble, Pharm.D., MPH, Pharmacist III
Dorthy Young, Ph.D., MHSA, Deputy Director of
Health Services
Chris A. Yount, MA, PMP, Staff Officer III

CHC Staff Present:

Sarah Boydston, Pharm.D.
Paige Clayton, Pharm.D.
Jacqueline Hedlund, M.D., MS
Shannon Hardwick, R.Ph.

Other Contract Staff Present:

Ben Banahan, Ph.D. UM School of Pharmacy
Leslie Leon, Pharm.D., Conduent
Eric Pittman, Pharm.D., UM School of
Pharmacy
Karen Powell, Pharm.D., Conduent
Lew Anne Snow, R.N., Conduent

Mississippi Pharmacy & Therapeutics Committee Meeting Minutes
August 14, 2018

Committee Attendance for SFY 2019

	AUG 2018	OCT 2018	FEB 2019	MAY 2019
Ali	x			
Brock	x			
Davis	x			
Dixit	x			
Hartness	x			
Maltby	x			
Minor	x			
Rodgers	x			
Sullivan	x			
Weiland				
Wilbanks				
Woo	x			

DRAFT

I. Call to Order

Dr. Logan Davis, Sit-In Chairperson, called the meeting to order at 10:01 a.m.

II. Introductions

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She introduced Change Healthcare, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Kirby recognized DOM contractors in the audience, including Dr. Leslie Leon, Dr. Karen Powell, Joyce Grizzle and Lew Ann Snow from Conduent, Drs. Ben Banahan and Eric Pittman from the University of Mississippi School of Pharmacy's MS-DUR Program and Dr. Paige Clayton, Dr. Sarah Boydston and Shannon Hardwick from Change Healthcare (CHC). Ms. Kirby recognized MississippiCAN contractors in the audience, including Drs. Jenni Grantham and Mike Todaro from Magnolia Health, Drs. Alfred Romay and Trina Stewart from Molina Healthcare and Dr. Heather Odem from UnitedHealthcare.

III. Administrative Matters

Ms. Kirby reminded guests that if they did not sign the sign-in sheet prior to entering the room, to please do so. She stated that copies of the agenda and the public comment guidelines are available at the sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 5 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting.

Ms. Kirby reviewed policies related to food and drink, cell phones and pagers, laptop usage, discussions in the hallways, and emergency procedures for the building.

Ms. Kirby stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Kirby reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members making motions. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no

later than September 13, 2018. Decisions will be announced no later than September 1, 2018 on the DOM website.

Ms. Kirby stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

Ms. Kirby reviewed Committee policies and procedures. She requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member. New members should sign the Confidentiality Agreement, Conflict of Interest Statement and Contact Information Forms.

IV. Approval of May 8, 2018 Meeting Minutes

Dr. Davis asked for additions or corrections to the minutes from the May 8, 2018 meeting. There were no further additions or corrections. The minutes stand approved.

V. PDL Compliance/Generic Percent Report Updates

Dr. Clayton provided an explanation of the PDL Compliance and Generic Percent reports.

- A.** Dr. Clayton reviewed the PDL Compliance Report; overall compliance for Q2 2018 was 98%.
- B.** Dr. Clayton reviewed the Generic Percent Report; overall generic utilization for Q2 2018 was 87.3%.

VI. Drug Class Announcements

Dr. Clayton reviewed the meeting format.

VII. Public Comments

Paige Akers from Vertex spoke in favor of Symdeko.
Brad Clay from Amgen spoke in favor of Aimovig.
Eric Hecht from Novo Nordisk spoke in favor of Novoeight, Rebinyn.
David Josey Jr from UMC Pediatrics advocated for Symdeko.
Shannon Sands from Sunovion spoke in favor of Lonhala Magnair.
Paige Akers from Vertex spoke in favor of Symdeko.

VIII. New Therapeutic Class Reviews

A. Factor Deficiency Products

CHC recommended that the following list be approved. A clinical discussion followed and the committee opted to vote per sub class.

For the Factor VIII Class: Dr. Minor moved to accept the recommendation with the addition of Nuwiq and Novoeight as preferred products. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval.

For the Von Willenbrand Agents: Dr. Ali moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was carried by unanimous approval. The combined approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
FACTOR VIII	
ADVATE ALPHANATE FEIBA NF HEMOFIL M HUMATE-P KOATE KOATE-DVI MONOCLATE-P NOVOEIGHT NUWIQ RECOMBINATE WILATE	ADYNOVATE AFSTYLA ELOCTATE KCENTRA KOGENATE FS KOVALTRY NOVOSEVEN RT OBIZUR VONVENDI XYNTHA XYNTHA SOLOFUSE

For the Factor IX Class: Dr. Minor moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
FACTOR IX	
ALPHANINE SD ALPROLIX BEBULIN BENEFIX IXINITY MONONINE PROFILNINE RIXUBIS	IDELVION REBINYN

For the Other Factor Class: Dr. Hartness moved to accept the recommendation with the addition of Fibryga as a preferred product. Dr. Minor seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
OTHER FACTOR PRODUCTS	
COAGADEX	CORIFACT

PREFERRED AGENTS	NON-PREFERRED AGENTS
FIBRYGA HEMLIBRA RIASTAP	TRETTEN

B. Atypical Antipsychotic Long Acting Injectables

(Financial review only). Effective 7-1-2018, DOM opened access to all beneficiaries to receive these medications thru the pharmacy POS system as the first additions for the Clinician Administered Drugs/Implantable Drug System Devices. DOM accepted the 2018 Supplemental Rebate offers for Aristada, Aristada Initio, Invega Sustenna, Invega Trinza, and Abilify Maintena.

IX. New Drug/New Generic Reviews

A. Aimovig

CHC recommended that Aimovig be made Non-Preferred in the Antimigraine category. Dr. Ali moved to accept the recommendation. Dr. Minor seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
	AIMOVIG (erenumab)

B. Erleada

CHC recommended that Erleada be made Non-Preferred in the Antineoplastics category. Dr. Sullivan moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below. *Let the minutes reflect that Dr. Minor left the meeting after this vote.

PREFERRED AGENTS	NON-PREFERRED AGENTS
AFINITOR (everolimus) BOSULIF (bosutinib) CAPRELSA (vandetanib) COMETRIQ (cabozantinib) COTELLIC (cobimetinib) GILOTRIF (afatanib) GLEEVEC (imatinib mesylate) ICLUSIG (ponatinib) IMBRUVICA (ibrutnib) INLYTA (axitinib) IRESSA (gefitinib) JAKAFI (ruxolitinib) MEKINIST (trametinib dimethyl sulfoxide) NEXAVAR (sorafenib) SPRYCEL (dasatinib)	ALECENSA (alectinib) ALUNBRIG (brigatinib) BRAFTOVI (encorafenib) ^{NR} CABOMETYX (cabozantinib s-malate) CALQUENCE (acalabrutinib) ERLEADA (apalutamide) FARYDAK (panobinostat) GLEOSTINE (lomustine) IBRANCE (palbociclib) ^{SmartPA} IDHIFA (enasidenib) imatinib KISQALI (ribociclib) LENVIMA (lenvatinib) ^{SmartPA} LYNPARZA (olaparib) ^{SmartPA} NERLYNX (neratinib maleate) MEKTOVI (binimetnib) ^{NR}

PREFERRED AGENTS	NON-PREFERRED AGENTS
STIVARGA (regorafenib) SUTENT (sunitinib) TAFINLAR (dabrafenib) TARCEVA (erlotinib) TASIGNA (nilotinib) TYKERB (lapatinib ditosylate) vandetanib VOTRIENT (pazopanib) XALKORI (crizotinib) ZELBORAF (vemurafenib) ZYDELIG (idelalisib) ZYKADIA (ceritinib)	RUBRACA (rucaparib) RYDAPT (midostaurin) TAGRISSO (osimertinib) VERZENIO (abemaciclib) XATMEP (methotrexate) ZEJULA (niraparib)

C. Osmolex ER

CHC recommended that Osmolex ER be made Non-Preferred in the Antiparkinson's Agents category. Dr. Ali moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
OTHERS	
amantadine bromocriptine carbidopa levodopa/carbidopa	GOCOVRI (amantadine) levodopa/carbidopa ODT levodopa/carbidopa/entacapone LODOSYN (carbidopa) OSMOLEX ER (amantadine) PARCOPA (levodopa/carbidopa) PARLODEL (bromocriptine) RYTARY ER (levodopa/carbidopa) SINEMET (levodopa/carbidopa) SINEMET CR (levodopa/carbidopa) STALEVO (levodopa/carbidopa/entacapone)

D. Symfi/Symfi-Lo and Cimduo

CHC recommended that Symfi/Symfi-Lo and Cimduo all be made Preferred in their respective Antiretrovirals sub-categories. Dr. Brock moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & INTEGRASE INHIBITORS	
BIKTARVY (bictegravir/emtricitabine/tenofovir) GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir) SYMFI (efavirenz/lamivudine/tenofovir) SYMFI-LO (efavirenz/lamivudine/tenofovir)	STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) TRIUMEQ (abacavir/lamivudine/ dolutegravir)
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & NON-NUCLEOSIDE RTIs	
ATRIPLA (efavirenz/emtricitabine/tenofovir) CIMDUO (lamivudine/tenofovir) ODEFSEY (emtricitabine/rilpivirine/tenofovir AF)	COMPLERA (emtricitabine/rilpivirine/tenofovir)

E. Lonhala Magnair

CHC recommended that Lonhala Magnair be made Non-Preferred in the Bronchodilators, Beta Agonists agents category. Tudorza Pressair will be made Preferred as part of the financial review of this category. .Dr. Hartness moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
INHALATION SOLUTION	
albuterol	BROVANA (arformoterol) levalbuterol LONHALA MAGNAIR (glycopyrrolate) metaproterenol PERFOROMIST (formoterol) XOPENEX (levalbuterol)
ANTICHOLINERGICS & COPD AGENTS	
ATROVENT HFA (ipratropium) ipratropium SPIRIVA HANDIHALER (tiotropium) TUDORZA PRESSAIR (aclidinium)	DALIRESP (roflumilast) INCRUSE ELLIPTA (umeclidinium) SEEBRI (glycopyrrolate) SPIRIVA RESPIMAT (tiotropium)

F. Daxbia

CHC recommended that Daxbia be made Non-Preferred in the Cephalosporins category. Dr. Brock moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
CEPHALOSPORINS – First Generation	
cefadroxil cephalexin capsules cephalexin suspension	cephalexin tablets DAXBIA (cephalexin) KEFLEX (cephalexin)

G. Symdeko

CHC recommended that Symdeko be made Non-Preferred in the Cystic Fibrosis category. Dr. Hartness moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
BETHKIS (tobramycin) KITABIS (tobramycin)	CAYSTON (aztreonam) COLY-MYCIN M (colistimethate sodium) KALYDECO (ivacaftor) ORKAMBI (lumacaftor/ivacaftor) PULMOZYME (dornase alfa) SYMDEKO (tezacaftor/ivacaftor)

PREFERRED AGENTS	NON-PREFERRED AGENTS
	TOBI (tobramycin) TOBI PODHALER (tobramycin) tobramycin

H. Rhopressa

CHC recommended that Rhopressa be made Preferred in the Ophthalmic, Glaucoma Agents category. Dr. Hartness moved to accept the recommendation. Dr. Dixit seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
RHO KINASE INHIBITORS	
RHOPRESSA (netarsudil)	

X. Division of Medicaid Update

Ms. Kirby announced that Jason Dees, D.O., has been named Interim Medical Director for the Division of Medicaid and that Molina Healthcare of Mississippi, Inc. will be the third MississippiCAN contractor beginning October 1, 2018.

Ms. Kirby reviewed the Clinician Administered Drug and Implantable Drug System Devices (CADD) category created to allow certain physician-administered drugs to be billed and reimbursed as either medical or pharmacy POS claims starting July 1, 2018.

Ms. Kirby reviewed the clinical edit for ADD/ADHD stimulant drugs that is being implemented, which will require the presence of an approved indication either in paid medical claims or submitted on the prescription claim for each stimulant product prescribed for both adults and children. The edit will become effective October 1, 2018.

XI. Other Business

XII. Next Meeting Date

The next meeting of the Pharmacy & Therapeutics Committee will be held on October 23, 2018 at 9:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi, unless otherwise notified.

XIII. Adjournment

The meeting adjourned at 12:15 p.m.